ResearchMoz added Latest Research Report titled ” Dyslipidemia Drugs Market: (By Drug Class – Statins, Bile Acid Resins, Fibric Acid and Omega-3 Fatty Acid Derivatives, Niacins, Others) – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 – 2023 ” to it’s Large Report database.
Dyslipidemia is a chronic metabolic syndrome, characterized by improper level of low density lipoprotein, high density lipoprotein, and triglycerides. This study on the dyslipidemia drugs market involves the analysis of a wide range of therapeutics that help patients to treat lipid disorders. The dyslipidemia drugs market promises lucrative growth opportunities for pharmaceutical manufacturers due to increasing demand and prescriptions of these medications. According to the Centers for Disease Control and Prevention, cholesterol abnormalities are rapidly increasing in developed regions such as North America and Europe. Moreover, several articles published in open journals stated that demand for lipid lowering drugs is increasing in countries such as China, India, and Japan. However, loss of patent exclusivity of molecules such as Crestor, Zetia, and Vytorin is expected to hamper the growth of the market during the forecast period.
Download free Sample PDF report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=329924
This report comprises a detailed study of various drug classes for the treatment of dyslipidemia. The dyslipidemia drugs market has been segmented into statins, bile acid resins, fibric acid derivatives, niacins, and others (combination drugs and cholesterol absorption inhibitors). The statins segment comprises combined market revenue of statin drugs such as atorvastatin, fluvastatin, rosuvastatin, pravastatin, simvastatin, pitavastatin, and lovastatin. The bile acid resins segment included resins such as Cholestyramine, Colestipol, Colesevelam, and Cholybar. The fibric acid, and omega-3 fatty acid derivatives segment comprises generic drugs such as Fenofibrate, Clofibrate, and Bezafibrate. Other branded omega-3 fatty acids include Lovaza, Vascespa, and Omtryg. Niacins includes drugs such as Niaspan, Slo-Niacin, and Niacor. The others segment encompasses market analysis of combination drug therapies such as Advicor, Vytorin, and Caduet, as well as cholesterol inhibitor drugs. The market size and forecast for each drug class has been provided for the period from 2013 to 2023. The report also provides the compound annual growth rate (% CAGR) for the forecast period from 2015 to 2023 for each drug class, considering 2013 to 2014 as the historical and base year, respectively.
Read All Pharmaceutical Market Research Reports @ http://www.researchmoz.us/pharmaceutical-market-reports-38.html
Table of Content
Chapter 1 Introduction
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
18.104.22.168 Secondary Research
22.214.171.124 Primary Research
1.4 List of Abbreviations
Chapter 2 Executive Summary
2.1 Market Snapshot: Dyslipidemia Drugs Market (2014 & 2023)
2.2 Dyslipidemia Drugs Market, by Drug Class, 2014 (USD Million)
2.2.1 Comparative Analysis: Dyslipidemia Drugs Market, by Geography, 2014 and 2023 (Value %)
Chapter 3 Market Overview
3.2 Epidemiology: Dyslipidemia
3.3 Etiology of Dyslipidemia
3.3.1 Primary Causes (genetic causes of dyslipidemia)
3.3.2 Secondary Causes (lifestyle factors)
3.4 Dyslipidemia Diagnostics
3.4.1 Serum Lipid Profile Measurement (total cholesterol, HDL, LDL, VLDL, etc.)
3.4.2 Other Tests (lipoprotein-A tests, apo lipoprotein B tests, etc.)
3.4.3 Secondary Causes Screening and Diagnostics
ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Albany NY, United States – 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Follow me on Blogger at: http://healthcare-research-report.blogspot.in/